United Health Products, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OQB
United Health Products, Inc. has entered into an agreement with NAMSA to serve as the regulatory sponsor for a new clinical study of its CelluSTAT Hemostatic Gauze, a key step in its FDA Premarket Approval application process.
OQB
United Health Products, Inc. has secured a $289,821 senior convertible promissory note and established a $4 million equity line with Alumni Capital LP to bolster its financial position and fund general corporate purposes.
OQB
8-K: United Health Products Announces Departure of Finance VP, CEO Assumes Interim Financial Officer Role
United Health Products, Inc. announced the resignation of Kristofer Heaton as Vice President of Finance and Principal Financial Officer, with CEO Brian Thom stepping in as interim Principal Financial Officer.
OQB
United Health Products announces its common shares have been uplisted to the OTCQB Venture Market and provides an update on its FDA application for CelluSTAT Hemostatic Gauze.
OQB
8-K: United Health Products Provides Update on FDA Premarket Approval Application for HemoStyp Gauze
United Health Products announced an update on its FDA Premarket Approval application for its HemoStyp gauze, including the need for additional clinical data.
OQB
United Health Products has further amended its Common Stock Purchase Agreement with White Lion Capital, modifying the purchase price calculation for shares.